SAN DIEGO, CA, Feb. 01, 2024 (GLOBE NEWSWIRE) — via NewMediaWire –Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: “SIGYD”, “SIGY”), a development-stage medical technology company, disclosed today that a 1-for-40 reverse split of its common stock was implemented on January 31, 2024. As a result of the split, the Company’s common stock will trade under the ticker symbol “SIGYD” for 20 business days and subsequently revert to trading under its historic symbol “SIGY” on February 29, 2024.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Pixalate’s March 2025 Top Grossing Mobile Apps in APAC: ‘SimCity’ Ranked No. 1 on Google Play Store in Japan; ‘OLX’ Led on Apple App Store in India; ‘Sudoku’ Ranked No. 1 on Apple App Store in Singapore - April 21, 2025
- Pixalate’s March 2025 Top Grossing Mobile & CTV Apps in LATAM: ‘ViX’ No. 1 on Roku, Amazon Fire TV & Samsung Smart TV in Mexico; ‘Space shooter’ Leads in Brazil on Google Play Store - April 21, 2025
- Pixalate’s March 2025 Top Grossing Mobile & CTV Apps in EMEA: ‘Block Blast!’ Tops Apple App Store in UK, Germany, Netherlands; ‘Hulu’ Led on Roku in UK - April 21, 2025
